Stocks · Healthcare · Biotechnology
Monte Rosa Therapeutics, Inc. GLUE
$10.27 -2.19% Close, Oct 5, 2026 · NASDAQ · Market cap $887.0M
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-2.18, down 826.7% year over year.
- Revenue over the last four quarters was $28.7M, down 83.9% from a year earlier, slowing from -73.1% a quarter earlier.
- Operating margin narrowed to -633.0% from 8.4% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 6%
- EPS growth (TTM, YoY)Bottom 4%
- FCF growth (TTM, YoY)Bottom 4%
- Revenue growth accelerationBottom 17%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 43%
- Gross marginTop 16%
- Operating marginBottom 15%
- Accruals (lower is better)Top 14%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 31%
- Free-cash-flow yieldTop 48%
- EBITDA / enterprise valueBottom 28%
- Sales / enterprise valueBottom 17%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 19%
- 6-month returnBottom 10%
- 1-year return vs S&P 500Top 33%
- Distance from 52-week highBottom 16%
- Trend checklist (0–4)Bottom 13%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 17%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 49%
- Upside to consensus price targetTop 24%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 17%
- Maximum drawdown, 3 yearsTop 41%
- Beta vs S&P 500 (lower is better)Bottom 33%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -73.1% | -83.9% | ↓ |
| EPS growth (YoY) | -2771.4% | -826.7% | ↑ |
| Gross margin | 100.0% | 92.9% | ↓ |
| Operating margin | 8.4% | -633.0% | ↓ |
| FCF margin | 13.4% | -111.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -83.9% | -73.1% | ↓ | Bottom 6% |
| EPS growth (TTM, YoY) | -826.7% | -2771.4% | ↑ | Bottom 4% |
| Gross margin | 92.9% | 100.0% | ↓ | Top 16% |
| Operating margin | -633.0% | 8.4% | ↓ | Bottom 15% |
| Net margin | -560.9% | 13.6% | ↓ | — |
| Free-cash-flow margin | -111.7% | 13.4% | ↓ | — |
| Return on invested capital | -28.2% | — | Bottom 43% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -19.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 71.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +399.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -40.76%
- Shareholder yield
- -40.76%
- Share count change, 1 year
- +38.1%
- Share count change, 3-year CAGR
- +19.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -29.4%
- Average 2-day reaction, last 8
- +1.8%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $26.25
- Target vs current price
- +155.6%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 78%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -13.0% | +0.6% | +2.2% | -8.9% | — |
| May 7, 2026 | -60.7% | -2.8% | -7.0% | -14.9% | -24.6% |
| Mar 17, 2026 | -53.6% | -2.0% | -8.1% | +7.0% | +1.0% |
| Nov 6, 2025 | +9.9% | +5.7% | +15.0% | +40.2% | +70.0% |
| Aug 7, 2025 | +60.2% | -3.0% | +1.8% | +12.6% | +198.4% |
| May 8, 2025 | +21690.9% | +9.6% | -3.9% | +20.0% | +26.8% |
| Mar 20, 2025 | +1379.1% | +5.4% | -18.1% | -34.2% | -26.7% |
| Nov 7, 2024 | +40.8% | +0.8% | -8.7% | -6.6% | -27.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.43 | -$0.38 | -13.0% | $9.0M |
| May 7, 2026 | -$0.45 | -$0.28 | -60.7% | $4.2M |
| Mar 17, 2026 | -$0.54 | -$0.35 | -53.6% | $2.8M |
| Nov 6, 2025 | -$0.33 | -$0.37 | +9.9% | $12.8M |
| Aug 7, 2025 | -$0.15 | -$0.38 | +60.2% | $23.2M |
| May 8, 2025 | $0.57 | -$0.00 | +21690.9% | $84.9M |
| Mar 20, 2025 | $0.23 | $0.02 | +1379.1% | $60.6M |
| Nov 7, 2024 | -$0.29 | -$0.49 | +40.8% | $9.2M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 29.06× | — | — | Bottom 17% |
| Free-cash-flow yield | -3.62% | — | — | Top 48% |
| Earnings yield | -21.23% | — | — | Bottom 31% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -23.4%
- 200-day average slope (20 days)
- -2.0%
- Distance from 50-day average
- -29.5%
- Distance from 200-day average
- -43.4%
- RSI (14)
- 22.5
- Relative volume
- 1.36×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 82.2%
- Volatility vs own 5-year history
- 28th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.45
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -59.4%
- Maximum drawdown, 3 years
- -64.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 3, 2021 | Oct 25, 2023 | -94.1% | 538 days | Not yet recovered |
| Jun 30, 2021 | Jul 13, 2021 | -18.1% | 8 days | 8 days (Jul 23, 2021) |
| Jun 24, 2021 | Jun 25, 2021 | -10.9% | 1 days | 3 days (Jun 30, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $887.0M
- EPS, diluted (TTM)
- -$2.18
- Revenue (TTM)
- $28.7M
- 52-week range
- $7.24 – $25.77
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $75.6M | $123.7M |
| Gross profit | $0 | $0 | -$6.2M | $67.5M | $115.3M |
| Operating income | -$72.9M | -$112.4M | -$143.3M | -$81.1M | -$54.2M |
| Net income | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| EPS (diluted) | -$1.59 | -$2.30 | -$2.63 | -$0.98 | -$0.59 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $60.6M | $84.9M | $23.2M | $12.8M | $2.8M | $4.2M | $9.0M |
| Net income | -$23.9M | $13.4M | $46.9M | -$12.3M | -$27.1M | -$46.1M | -$44.5M | -$43.4M |
| EPS (diluted) | -$0.29 | $0.22 | $0.57 | -$0.20 | -$0.44 | -$0.70 | -$0.53 | -$0.51 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$59.4M | -$92.5M | -$43.8M | $42.0M | -$22.8M |
| Capital expenditure | -$9.7M | -$12.9M | -$19.0M | -$4.0M | -$4.7M |
| Free cash flow | -$69.1M | -$105.4M | -$62.8M | $38.0M | -$27.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $237.8M | $20.1M | $27.5M | $303,000 | $30.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $621.1M
- Total assets
- $696.1M
- Total liabilities
- $211.0M
- Total debt
- $38.0M
- Net debt
- -$52.1M
- Shareholders’ equity
- $487.3M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 19,265,990
- Days to cover
- 17.08
- Change vs previous report
- +6.6%
FINRA short interest, settlement date Sep 15, 2026.